SCHEMBL328969

SCHEMBL328969

CC1(C)C(=O)N(C2C3CC4CC2CC(C#N)(C4)C3)CC1CO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 14/20 0.48
HSD11B2 P80365 8/20 0.48
SMYD2 Q9NRG4 3/20 0.35
CYP3A4 P08684 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL328788 0.83 HSD11B1 (0.51) HSD11B1HSD11B2SMYD2CYP3A4HTT
SCHEMBL4792811 0.78 HSD11B1 (0.76) HSD11B1HSD11B2CYP3A4
SCHEMBL328782 0.75 HSD11B1 (0.50) HSD11B1HSD11B2SMYD2CYP3A4HTT
SCHEMBL328751 0.71 HSD11B1 (0.46) HSD11B1HSD11B2SMYD2CYP3A4HTT
SCHEMBL19256171 0.65 HSD11B1 (1.00) HSD11B1HSD11B2CYP3A4
SCHEMBL3010470 0.62 SMYD2 (0.39) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL3010475 0.62 SMYD2 (0.39) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL30158926 0.62 CYP3A4 (0.41) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL19689355 0.62 CYP3A4 (0.41) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL19689354 0.62 CYP3A4 (0.41) SMYD2CYP3A4HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007719-B1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LAB (US) 2012-05-02 EP disclosed
EP-2407452-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme Abbott Laboratories (US) 2012-01-18 EP disclosed
US-7737137-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2010-06-15 US disclosed
US-20080312214-A1 Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme ABBOTT LABORATORIES (US) 2008-12-18 US disclosed
US-7435833-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2008-10-14 US disclosed
US-20080076819-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2008-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076819-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME HSD11B1, HSD11B2, HSD17B1 HSD11B1 1/4885HSD11B2 2/4885SMYD2 2750/4885
US-20080312214-A1 Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD11B2 3/4885SMYD2 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.